Alivexis Inc. and Melodia Therapeutics AG have entered into an exclusive license agreement for the worldwide development, manufacturing and commercialization of Alivexis’ MDI-0151, a novel cathepsin C inhibitor identified in Alivexis’ MOD-A discovery program.
Ose Immunotherapeutics SA has presented preclinical data on its mRNA therapeutic platform for the treatment of inflammatory and autoimmune disorders. The platform has been designed for the local delivery of mRNA into inflammatory tissue using lipid nanoparticles (LNPs). Interleukin-35 (IL-35) has been shown in preclinical studies to have a key role in controlling several immune-related disorders, including autoimmune diseases.
Exo Therapeutics Inc. has presented data on its preclinical program targeting TBK1/STING interaction of the cGAS-STING pathway. The company has identified potent, selective exosite-targeted TBK1/STING inhibitors, optimized properties toward development candidate nomination and demonstrated efficacy across preclinical models.
Coming off a presentation at the European Alliance of Associations for Rheumatology meeting, where a single report of disease recurrence in a lupus patient overshadowed promising early data for Kyverna Therapeutics Inc.’s autoimmune candidate, KYV-101, the Emeryville, Calif.-based company rallied on news of a case report describing the first use of the CD19-targeting CAR T-cell therapy in a patient with stiff-person syndrome, a rare, progressive neurological autoimmune disorder for which there is limited treatment.
Preliminary data show Biotron Ltd.’s lead compound BIT-225 met the primary objectives of the phase II BIT225-011 trial, a longitudinal, open-label trial designed to characterize the effect of the compound added to ongoing, suppressive antiretroviral therapy in HIV-1-infected, treatment-experienced patients who achieved only partial immune reconstitution.
The adverse effects of PD-1 blockers on the CNS observed in cancer patients could occur through their effects on an enzyme that activates microglia. Pharmacological inhibition of the enzyme in mice reduced microglial activation and cognitive deficit without altering the antitumor capacity of the immunotherapy.
At the recent EULAR meeting, a presentation by Nanjing Leads Biolabs Co. Ltd. covered the discovery of LBL-047, a novel bifunctional fusion protein targeting both plasmacytoid dendritic cells (pDCs) and B cells; it is being developed for the treatment of autoimmune diseases.
Following a day of deals that collectively bring a potential $3.75 billion into three biopharma companies – namely Ascidian Therapeutics Inc., Belharra Therapeutics Inc. and Mabcare Therapeutics – researchers will be busy discovering new therapies for neurological and immunological diseases, and advancing globally a candidate for solid tumors.
KYV-201 is an investigational allogeneic anti-CD19 CAR T-cell therapy candidate being developed by Kyverna Therapeutics Inc. for the treatment of B-cell-driven autoimmune diseases.
The adverse effects of PD-1 blockers on the CNS observed in cancer patients could occur through their effects on an enzyme that activates microglia. Pharmacological inhibition of the enzyme in mice reduced microglial activation and cognitive deficit without altering the antitumor capacity of the immunotherapy.
RSS
